Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
ConclusionsDenosumab biosimilar QL1206 had promising efficacy, tolerable safety, and pharmacokinetics equivalent to denosumab and could benefit patients with bone metastases from solid tumors.Clinical Trial RegistrationClinicalTrials.gov Identifier: NCT04550949, retrospectively registered on 16 September, 2020
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | China Health | Clinical Trials | Drugs & Pharmacology | Study | Xgeva